NeuroVive Pharmaceutical has completed the closure of its dormant subsidiary in Lyon, France.

The closure of the subsidiary NeuroVive France SARL is a natural consequence of the company’s previously communicated decision that it will not pursue development of CicloMulsion.

Accordingly, all agreements related to the research partnership with Hospices Civils de Lyon (HCL) and Professor Michel Ovize, including the OPeRa (Organ Protection & Replacement) have been terminated.